Kathryn Packman Selected Research

RO0281501

8/2006

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kathryn Packman Research Topics

Disease

32	Neoplasms (Cancer) 01/2022 - 12/2002
6	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 12/2002
3	Multiple Myeloma 01/2020 - 01/2020
3	Melanoma (Melanoma, Malignant) 02/2012 - 07/2010
3	Colorectal Neoplasms (Colorectal Cancer) 02/2012 - 01/2009
2	Neoplasm Metastasis (Metastasis) 01/2022 - 03/2012
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 01/2020
2	Adenocarcinoma 01/2021 - 07/2007
2	Breast Neoplasms (Breast Cancer) 07/2007 - 02/2003
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2021
1	Hematologic Neoplasms (Hematological Malignancy) 12/2021
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 12/2021
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2020
1	Lung Neoplasms (Lung Cancer) 09/2019
1	Osteosarcoma (Osteogenic Sarcoma) 07/2014
1	Leukemia 02/2014
1	Colonic Neoplasms (Colon Cancer) 08/2011

Drug/Important Bio-Agent (IBA)

4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2012 - 03/2009
4	Phosphotransferases (Kinase)IBA 08/2011 - 11/2006
3	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 05/2011
3	Proteins (Proteins, Gene)FDA Link 01/2016 - 07/2010
3	AndrogensIBA 04/2013 - 12/2002
3	VemurafenibIBA 02/2012 - 07/2010
3	Bevacizumab (Avastin)FDA Link 01/2009 - 07/2007
3	Capecitabine (Xeloda)FDA Link 01/2009 - 07/2007
2	Androgen Receptor AntagonistsIBA 01/2021 - 01/2021
2	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2020 - 01/2020
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 09/2019 - 08/2006
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2016 - 01/2009
2	Antineoplastic Agents (Antineoplastics)IBA 01/2016 - 08/2006
2	Pharmaceutical PreparationsIBA 09/2013 - 01/2010
2	RG7112IBA 05/2013 - 04/2013
2	Codon (Codons)IBA 02/2012 - 07/2010
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 06/2011 - 10/2009
2	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 06/2011 - 10/2009
2	Hormones (Hormone)IBA 05/2011 - 12/2002
2	nutlin 3IBA 05/2011 - 02/2006
2	Mitogen-Activated Protein KinasesIBA 01/2010 - 03/2009
2	Estrogen ReceptorsIBA 07/2007 - 02/2003
1	Immunoglobulins (Immunoglobulin)IBA 01/2022
1	rucaparibIBA 01/2022
1	olaparibIBA 01/2022
1	niraparibIBA 01/2022
1	talazoparibIBA 01/2022
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	A-Form DNA (A-DNA)IBA 01/2022
1	JNJ-64619178IBA 12/2021
1	RNA Splicing FactorsIBA 12/2021
1	JNJ-63576253IBA 01/2021
1	LigandsIBA 01/2021
1	amivantamab-vmjwIBA 10/2020
1	FucoseIBA 10/2020
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	blinatumomabIBA 01/2020
1	AntigensIBA 01/2020
1	B-Cell Maturation AntigenIBA 01/2020
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2020
1	Bispecific AntibodiesIBA 01/2020
1	erdafitinibIBA 09/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 09/2019
1	AntibodiesIBA 01/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	RO8994IBA 08/2014
1	RG7388IBA 07/2014
1	SuspensionsIBA 02/2014
1	Small Interfering RNA (siRNA)IBA 02/2014
1	Lipid NanoparticlesIBA 02/2014
1	RG7212IBA 10/2013
1	TWEAK ReceptorIBA 10/2013
1	ATSP-7041IBA 09/2013
1	Peptides (Polypeptides)IBA 09/2013
1	Transcription Factors (Transcription Factor)IBA 05/2013
1	Biomarkers (Surrogate Marker)IBA 04/2013
1	Angiogenesis InhibitorsIBA 02/2013
1	hepsinIBA 03/2012
1	Proto-Oncogene Proteins B-rafIBA 01/2012
1	Interleukin-6 (Interleukin 6)IBA 06/2011
1	Interleukin-8 (Interleukin 8)IBA 06/2011
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 07/2010
1	MitogensIBA 07/2010
1	2- (4- (4- (2,3- dihydroxy- propoxy)phenyl)- 2,5- dioxo- imidazolidin- 1- yl)- N- (2- fluoro- 4- iodo- phenyl)- 3- phenylbutyramideIBA 01/2010
1	(2S,3S)- 2- ((R)- 4- (4- (2- hydroxyethoxy)phenyl)- 2,5- dioxo- imidazolidin- 1- yl)- 3- phenyl- N- (4- propionylthiazol- 2- yl)butyramideIBA 03/2009
1	MAP Kinase Kinase 1IBA 03/2009
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2009
1	Taxoids (Taxanes)IBA 07/2007
1	AnthracyclinesIBA 07/2007
1	Retinoblastoma ProteinIBA 11/2006
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 08/2006
1	RO0281501IBA 08/2006
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 08/2006
1	Gadolinium DTPA (Magnevist)FDA Link 08/2006
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 08/2006
1	Cholecalciferol (Vitamin D3)FDA Link 02/2003
1	Vitamin D FDA LinkGeneric 02/2003
1	Estrogens (Estrogen)FDA Link 02/2003
1	seocalcitolIBA 02/2003

Therapy/Procedure

14	Therapeutics 01/2022 - 02/2003
3	Castration 01/2021 - 05/2011
1	Oral Administration 04/2013